keyword
MENU ▼
Read by QxMD icon Read
search

Keynote

keyword
https://www.readbyqxmd.com/read/29330126/recent-progress-in-the-discovery-of-myeloid-differentiation-2-md2-modulators-for-inflammatory-diseases
#1
REVIEW
Lingfeng Chen, Weitao Fu, Lulu Zheng, Yi Wang, Guang Liang
Myeloid differentiation protein 2 (MD2), together with Toll-like receptor 4 (TLR4), binds lipopolysaccharide (LPS) with high affinity, inducing the formation of the activated homodimer LPS-MD2-TLR4. MD2 directly recognizes the Lipid A domain of LPS, leading to the activation of downstream signaling of cytokine and chemokine production, and initiation of inflammatory and immune responses. However, excessive activation and potent host responses generate severe inflammatory syndromes such as acute sepsis and septic shock...
January 9, 2018: Drug Discovery Today
https://www.readbyqxmd.com/read/29299419/keynote-028-how-do-we-use-immunotherapy-in-small-cell-lung-cancer
#2
EDITORIAL
Jose M Pacheco, D Ross Camidge
No abstract text is available yet for this article.
December 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29299418/pembrolizumab-in-advanced-pretreated-small-cell-lung-cancer-patients-with-pd-l1-expression-data-from-the-keynote-028-trial-a-reason-for-hope
#3
EDITORIAL
Alejandro Navarro, Enriqueta Felip
No abstract text is available yet for this article.
December 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29287046/2017-visionary-leader-maureen-maurano
#4
Tara Floyd
The following manuscript is the winning 2017 Richard Hader Visionary Leader Award entry submitted to Nursing Management in recognition of Maureen Maurano, BSN, RN, nurse manager of the neonatal intensive care unit at Children's National Health System in Washington, D.C. Ms. Maurano was formally recognized for her achievements before the Keynote Address at Congress2017, October 4, in Las Vegas, Nev. There, she received the award, sponsored by Hackensack Meridian Health.
January 2018: Nursing Management
https://www.readbyqxmd.com/read/29284202/pembrolizumab-in-asia-pacific-patients-with-advanced-head-and-neck-squamous-cell-carcinoma-analyses-from-keynote-012
#5
Makoto Tahara, Kei Muro, Yasuhisa Hasegawa, Hyun Cheol Chung, Chia-Chi Lin, Bhumsuk Keam, Kenichi Takahashi, Jonathan D Cheng, Yung-Jue Bang
KEYNOTE-012 was a phase Ib, multicohort study designed to investigate efficacy and safety of pembrolizumab in advanced solid tumors. Results from the subset of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) from the Asia-Pacific region are reported. Patients with recurrent/metastatic HNSCC, measurable disease (Response Evaluation Criteria in Solid Tumors, version 1.1 [RECIST v1.1]), and Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 were eligible for enrollment in the HNSCC expansion cohort...
December 28, 2017: Cancer Science
https://www.readbyqxmd.com/read/29284010/safety-and-antitumor-activity-of-the-anti-pd-1-antibody-pembrolizumab-in-patients-with-advanced-colorectal-carcinoma
#6
Bert H O'Neil, John M Wallmark, David Lorente, Elena Elez, Judith Raimbourg, Carlos Gomez-Roca, Samuel Ejadi, Sarina A Piha-Paul, Mark N Stein, Albiruni R Abdul Razak, Katia Dotti, Armando Santoro, Roger B Cohen, Marlena Gould, Sanatan Saraf, Karen Stein, Sae-Won Han
BACKGROUND: Colorectal cancers (CRCs) expressing programmed death ligand 1 (PD-L1) have poor prognosis. In the multicohort KEYNOTE-028 trial, the anti-PD-1 antibody pembrolizumab was evaluated in 20 PD-L1-positive advanced solid tumors. Herein, we report results for the advanced CRC cohort. METHODS: Patients with advanced, treatment-resistant PD-L1-positive carcinoma of the colon or rectum were enrolled, regardless of microsatellite instability (MSI) status. Pembrolizumab 10 mg/kg was administered every 2 weeks for up to 2 years or until disease progression/unacceptable toxicity...
2017: PloS One
https://www.readbyqxmd.com/read/29283791/durable-complete-response-after-discontinuation-of-pembrolizumab-in-patients-with-metastatic-melanoma
#7
Caroline Robert, Antoni Ribas, Omid Hamid, Adil Daud, Jedd D Wolchok, Anthony M Joshua, Wen-Jen Hwu, Jeffrey S Weber, Tara C Gangadhar, Richard W Joseph, Roxana Dronca, Amita Patnaik, Hassane Zarour, Richard Kefford, Peter Hersey, Jin Zhang, James Anderson, Scott J Diede, Scot Ebbinghaus, F Stephen Hodi
Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including complete response (CR) in about 15% of patients. Data are limited on potential predictors of CR and patient disposition after pembrolizumab discontinuation after CR. We describe baseline characteristics and long-term follow-up in patients who experienced CR with pembrolizumab in the KEYNOTE-001 study ( ClinicalTrials.gov identifier: NCT01295827). Patients and Methods Patients with ipilimumab-naive or -treated advanced/metastatic melanoma received one of three dose regimens of pembrolizumab...
December 28, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29278600/ovarian-cancer-prevention-screening-and-early-detection-report-from-the-11th-biennial-ovarian-cancer-research-symposium
#8
Jeremy Chien, Elizabeth M Poole
OBJECTIVE: The aim of this study is to provide a summary report on recent research advances in ovarian cancer prevention, screening, and early detection that were presented at the 11th Biennial Ovarian Cancer Research Symposium in Seattle, Wash. METHODS: At the symposium, researchers from around the world participated in the poster, invited oral presentation and keynote presentation, and discussed the latest advances in the areas of cancer prevention, screening, and early detection...
November 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29278599/meeting-report-from-the-2016-11th-biennial-ovarian-cancer-research-symposium-mechanisms-of-initiation-and-progression-of-ovarian-cancers
#9
Jeremy Chien, Geeta Mehta
OBJECTIVE: The aim of this study was to review the latest research advances on the mechanisms of initiation and progression of ovarian cancer. METHODS: At the 11th Biennial Ovarian Cancer Research Symposium, which was held in Seattle, Washington in September 2016, leaders in ovarian cancer research convened to present and discuss current advances and future directions in ovarian cancer research. RESULTS: One session was dedicated to Mechanisms of Initiation and Progression of Ovarian Cancer, and included a keynote presentation from Dr Ronny Drapkin, MD (University of Pennsylvania), and an invited oral presentation from Laising Yen, PhD (Baylor College of Medicine)...
November 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29232184/feasibility-and-safety-of-intrathoracic-biopsy-and-repeat-biopsy-for-evaluation-of-programmed-cell-death-ligand-1-expression-for-immunotherapy-in-non-small-cell-lung-cancer
#10
Emily B Tsai, Kelsey Pomykala, Kathleen Ruchalski, Scott Genshaft, Fereidoun Abtin, Antonio Gutierrez, Hyun J Kim, Alice Li, Carlos Adame, Ashkan Jalalian, Brian Wolf, Edward B Garon, Jonathan W Goldman, Robert Suh
Purpose To determine feasibility and safety of biopsy and repeat biopsy for assessment of programmed cell death ligand-1 (PD-L1) status. Materials and Methods This retrospective analysis reviewed 101 patients who underwent transthoracic core needle biopsy for the KEYNOTE-001 (MK-3475) clinical trial of pembrolizumab, an antiprogrammed cell death-1 therapy for non-small cell lung cancer, from May 2012 to September 2014. Sixty-one male patients (mean age, 66.1 years; range 36-83 years) and 40 female patients (mean age, 66...
December 12, 2017: Radiology
https://www.readbyqxmd.com/read/29223672/education-and-the-pediatric-surgeon
#11
REVIEW
Joe I Curry, Celeste Hollands
There have been many changes in the domain of clinical surgery over the last 2 decades, but probably none more so than in education. The British Association of Pediatric Surgeons recognizes the importance of this topic and has commissioned a special session on this subject jointly with the International Pediatric Endosurgery Group. Free papers presented on a number of educational subjects and specific topics of recruitment and simulation were covered in invited lectures. The session was completed with a keynote lecture from the renowned educationalist Professor Roger Kneebone...
November 13, 2017: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/29219016/pembrolizumab-in-the-treatment-of-advanced-urothelial-cancer
#12
Kevin T Lundgren, Matthew S Farina, Joaquim Bellmunt
Pembrolizumab is a humanized monoclonal antibody that targets PD-1. In the Phase III trial KEYNOTE-045, pembrolizumab was associated with a significant overall survival benefit when compared with docetaxel, paclitaxel and vinflunine in second line metastatic urothelial carcinoma (UC). Additionally, in the first line, early results from an interim analysis of the Phase II trial Keynote-052 study indicated that pembrolizumab is efficacious for cisplatin-ineligible patients. Based on data from these trials, pembrolizumab was the most recent among the five checkpoint inhibitors tested in UC to be approved by the US FDA in May 2017...
December 2017: Future Oncology
https://www.readbyqxmd.com/read/29209527/pembrolizumab-as-second-line-therapy-in-non-small-cell-lung-cancer-in-northern-norway-budget-impact-and-expected-gain-a-model-based-analysis
#13
Jan Norum, Margareth Aarag Antonsen, Terje Tollåli, Khalid Al-Shibli, Gry Andersen, Kristin Helene Svanqvist, Nina Helbekkmo
Background: Pembrolizumab is a new drug approved in several countries for second-line therapy in non-small cell lung cancer (NSCLC) being programmed cell death ligand (PD-L1) positive. This drug has a high cost, and the cost-effectiveness ratio has been debated. Patients and methods: The budget impact to the Northern Norwegian Regional Health Authority trust of implementing pembrolizumab in second-line therapy in patients with PD-L1-positive NSCLC was calculated...
2017: ESMO Open
https://www.readbyqxmd.com/read/29193521/assembly-of-insect-hormone-enthusiasts-at-nasu-highland-japan-report-of-the-3rd-international-insect-hormone-21st-ecdysone-workshop
#14
Ryusuke Niwa, Takashi Nishimura
The 3rd International Insect Hormone (21st Ecdysone) Workshop (IIHW2017) was held in July 2017 at Nasu Highland, Japan. In the 40 years of the workshop's history, this was the first to be held in an Asian country. A total of 109 insect hormone researchers from 18 countries (62 overseas and 47 domestic participants) attended IIHW2017. During the workshop, all participants stayed on-site at the venue's hotel; this was ideal for fostering communication between participants, in particular, interactions between principal investigators and young scientists...
November 29, 2017: Genes to Cells: Devoted to Molecular & Cellular Mechanisms
https://www.readbyqxmd.com/read/29177698/evolution-of-early-phase-clinical-trials-in-oncology
#15
REVIEW
Nam Q Bui, Shivaani Kummar
The therapeutic armamentarium for the treatment of cancer has rapidly evolved with the advent of molecularly targeted and immuno-oncology agents. Dramatic and prolonged responses observed in patients with advanced cancers have created excitement and promise for expedited development of effective new treatments. However, this has also necessitated a rethinking of our early phase clinical trial designs and the process of optimally developing a novel agent. In this review, we discuss the current state and future directions of phase I clinical trials in oncology...
November 24, 2017: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
https://www.readbyqxmd.com/read/29171176/metastasis-specific-patterns-of-response-and-progression-with-anti-pd-1-treatment-in-metastatic-melanoma
#16
Jenny Hj Lee, Megan Lyle, Alexander M Menzies, Matthew Mk Chan, Serigne Lo, Arthur Clements, Matteo S Carlino, Richard F Kefford, Georgina V Long
This study evaluated patterns of response as discerned by comprehensive metastasis-specific analysis in metastatic melanoma patients receiving anti-PD-1 antibodies. Bi-dimensional measurements of every metastasis in patients enrolled in the KEYNOTE-001 trial at a single institution were obtained at baseline and throughout treatment. Twenty-seven evaluable patients had 399 baseline metastases measurable on CT imaging. Complete response (CR) which occurred in 52.6% of metastases was smaller (mean 223mm(2) vs...
November 24, 2017: Pigment Cell & Melanoma Research
https://www.readbyqxmd.com/read/29163851/checkpoint-inhibitors-in-endometrial-cancer-preclinical-rationale-and-clinical-activity
#17
REVIEW
Gloria Mittica, Eleonora Ghisoni, Gaia Giannone, Massimo Aglietta, Sofia Genta, Giorgio Valabrega
Context: Treatment of advanced and recurrent endometrial cancer (EC) is still an unmet need for oncologists and gynecologic oncologists. The Cancer Genome Atlas Research Network (TCGA) recently provided a new genomic classification, dividing EC in four subgroups. Two types of EC, the polymerase epsilon (POLE)-ultra-mutated and the microsatellite instability-hyper-mutated (MSI-H), are characterized by a high mutation rate providing the rationale for a potential activity of checkpoint inhibitors...
October 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/29145737/pembrolizumab-as-first-line-therapy-for-metastatic-non-small-cell-lung-cancer
#18
Martin Reck
This review describes trials evaluating the monoclonal antibody pembrolizumab (an immunotherapy that blocks the interaction between programmed death-1 and programmed death-ligand 1 and 2 [PD-L1/PD-L2]) as first-line therapy for advanced non-small-cell lung cancer (NSCLC). In the Phase III KEYNOTE-024 study, pembrolizumab monotherapy significantly improved progression-free survival (primary end point) and overall survival, and was associated with fewer adverse events compared with platinum-based chemotherapy in patients with NSCLC with PD-L1 expression on ≥50% of tumor cells...
November 17, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29135283/10th-annual-symposium-on-self-monitoring-of-blood-glucose-april-27-29-2017-warsaw-poland
#19
Christopher G Parkin, Anita Homberg, Rolf Hinzmann
International experts in the field of diabetes and diabetes technology met in Warsaw, Poland, for the 10th Annual Symposium on Self-Monitoring of Blood Glucose. The goal of these meetings is to establish a global network of experts to facilitate new collaborations and research projects that can improve the lives of people with diabetes. The 2017 meeting comprised a comprehensive scientific program, parallel interactive workshops, and four keynote lectures.
November 14, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/29133982/combined-aesthetic-interventions-for-prevention-of-facial-ageing-and-restoration-and-beautification-of-face-and-body
#20
Sabrina Fabi, Tatjana Pavicic, André Braz, Jeremy B Green, Kyle Seo, Jani Aj van Loghem
The Merz Institute of Advanced Aesthetics Expert Summit was held in Prague, Czech Republic, from 19-20 November 2016. The meeting had a distinct advisory board character and invited aesthetic practitioners from all over the world to hear an international faculty present a range of keynote lectures and conduct live injection sessions with an emphasis on recent developments in combination aesthetic interventions for face and body rejuvenation and beautification. Aging is associated with changes in bones, muscles, ligaments, adipose tissue, and skin and, moreover, involves interactions among these tissue types...
2017: Clinical, Cosmetic and Investigational Dermatology
keyword
keyword
56519
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"